Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

PHARMACOECONOMIC ANALYSIS OF BRENTUXIMAB VEDOTIN THERAPY IN RELAPSED OR REFRACTORY CD30+ SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA IN PATIENTS OVER 18 YEARS OF AGE: HEALTH BUDGET IMPACT ANALYSIS

https://doi.org/10.17749/2070-4909.2017.10.1.039-045

Full Text:

Abstract

Objectives. To provide a pharmacoeconomic analysis of brentuximab vetodin therapy in relapsed or refractory CD30+ systemic anaplastic large-cell lymphoma in patients over 18 years of age.

Methods. Recommendations to carry out a budget impact analysis in theRussian Federation (2016) were used.

Results. The analysis covered a period of 3 years. The target population of patients with relapsed or refractory CD30+ systemic anaplastic large cell lymphoma numbered 345 individuals. The results indicate that the introduction of brentuximab vetodin in the List of vital and essential drugs and the Program of state-guaranteed free medical care will not increase the costs of the treatment in patients with relapsed or refractory CD30+ systemic anaplastic large cell lymphoma.

Conclusion. The brentuximab vetodin therapy of relapsed or refractory CD30+ systemic anaplastic large cell lymphoma is an economically reasonable and resource-saving medical modality. 

About the Authors

A. S. Kolbin
The first St. Petersburg State Medical University named after Academician Pavlov; Saint Petersburg State University
Russian Federation

Kolbin Aleksei Sergeevich – MD, professor, head of department of clinical pharmacology and evidence-based medicine, First St. Petersburg State Medical University; Professor of the Department of Farmakology of St. Petersburg State University. 

Address: ul. L’va Tolstogo, 6-8, St. Petersburg, Russia, 197022



I. A. Vilum
The first St. Petersburg State Medical University named after Academician Pavlov; St. Petersburg multi-center
Russian Federation

Vilyum Irina Aleksandrovna – assistant of professor, Department of clinical pharmacology and evidence-based medicine, First St. Petersburg State Medical University.

Аddress: ul. L’va Tolstogo, 6-8, St. Petersburg, Russia, 197022 



М. A. Proskurin
Saint Petersburg State University
Russian Federation

Proskurin Maksim Alexandrovich – researcher. 

 Аddress: Universitetskii pr., 35, Saint-Petersburg, Russia, 198504



Yu. E. Balykina
Saint Petersburg State University
Russian Federation
Аddress: Universitetskii pr., 35, Saint-Petersburg, Russia, 198504


References

1. Russian clinical recommendations on diagnostics and treatment of lymphoproliferative disorders. Under the guidance of Professor I.V. Poddubnaya, Professor V.G. Savchenko [Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniyu limfoproliferativnykh zabolevanii. Pod rukovodstvom prof. I.V. Poddubnoi, prof. V.G. Savchenko (in Russian)]. Moscow. 2016; 324 s.

2. Jacobsen E. Anaplastic large-cell lymphoma, T-null-cell type. Oncologist. 2006; 11: 831-840.

3. Tilly H., Gaulard P., Lepage E., et al. Primary anaplastic largecell lymphoma in adults: Clinical presentation, immunophenotype, and outcome. Blood. 1997; 90: 3727-3734.

4. Savage K. J., Harris N. L., Vose J.M., et al. ALK-anaplastic largecell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: Report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008; 111: 5496-5504.

5. Hapgood G., Savage K. J.X. Challenges and future directions in peripheral T-cell lymphoma. Hematol Oncol. 2015; 33 (1): 56-61.

6. Russian clinical recommendations on diagnostics and treatment of lymphoproliferative disorders. Under the guidance of Professor I.V. Poddubnaya, Professor V.G. Savchenko [Rosciiskie klinicheskie rekomendatsii po diagnostike i lecheniyu limfoproliferativnykh zabolevanii. Pod rukovodstvom prof. I.V. Poddubnoi, prof. V.G. Savchenko (in Russian)]. Moscow. 2014; 128.

7. Tumyan G.S. Klinicheskaya onkogematolologiya. Fundamental’nye issledovaniya i klinicheskaya praktika. 2015; 8 (4): 455-470.

8. Rodriguez J., Munsell M., Yazji S., et al. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol. 2001; 19: 3766-3770.

9. Moskowitz C. H., Nimer S.D., Glassman J.R., et al. The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma. Bone Marrow Transplant. 1999; 23: 561-567.

10. Shipp M.A., Abeloff M.D., Antman K. H., et al. International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin’s Lymphomas: Report of the jury. J Clin Oncol. 1999; 17: 423-429.

11. ProB., et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012; 30 (18): 2190-6.

12. Chao-Ming Lai C-M., et al. Brentuximab vedotin: treatment role for relapsed refractory systemic anaplastic large-cell lymphoma. Expert Review of Hematology. 2013; 6: (4): 361-373.

13. Fanale M.A., et al. Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30 Peripheral T-Cell Lymphomas: Results of a Phase I Study. J Clin Oncol. 2014; 32: 3137-3143.

14. Al’-Radi L.S., Baryakh E.A., Belousova I.  E., et al. Clinical practice guidelines for the diagnosis and treatment of lymphoproliferative disorders. Association of oncologists of Russia. URL: http://oncology-association.ru/docs/recomend/2016/59klin-rek.pdf. Accessed: 10.12.2016.

15. Malignant neoplasms in Russia in 2015 (morbidity and mortality). Edited by A. D. Kaprina, V. V. Stalinskogo, G. V. Petrova [Zlokachestvennye novoobrazovaniya v Rossii v 2015 godu (zabolevaemost’ i smertnost’). Pod redaktsiei A. D. Kaprina, V. V. Starinskogo, G. V. Petrovoi (in Russian)]. Moscow. 2016.

16. Guidelines for the assessment of the impact of the budget in the framework of the program of state guarantees of free rendering to citizens of medical aid. Fsbi “ZECKE” Ministry of health of Russia. Approved by order of the fgbi “ZECKE” Ministry of health of Russia from 23 December 2016 No 145-od. [Metodicheskie rekomendatsii po otsenke vliyaniya na byudzhet v ramkakh realizatsii programmy gosudarstvennykh garantiĭ besplatnogo okazaniya grazhdanam meditsinskoĭ pomoshchi. FGBU «TsEKKMP» Minzdrava Rossii. Utverzhdeny prikazom FGBU «TsEKKMP» Minzdrava Rossii ot «23» dekabrya 2016 g. No 145-od. (in Russian)]. Moscow. 2016.

17. Brosa M., Gisbert R., Rodríguez Barrios J.M, Soto J. Principios, métodos y aplicaciones del análisisdel impacto presupuestario en sanidad. Pharmacoeconomics Spanish Research Articles. 2005; 2: 65-79.

18. Basic concepts in health technology assessment: method. allowance. Under. Edited by A.S. Kolbin, Zyryanov S.K., Belousov D.Yu. [Osnovnye ponyatiya v otsenke meditsinskikh tekhnologii: metod. posobie. Pod. red. A.S. Kolbina, S.K. Zyryanova, D.Yu. Belousova (in Russian)]. Moscow. 2013; 42 s.

19. Forero-Torres A., Leonard J.P., Younes A., et al. A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol. 2009; 146: 171-179.

20. NCCN, Guidelines. Version 1.2016.

21. Assessment of medical care to patients c Hodgkin’s Lymphoma and systemic anaplastic large cell lymphoma. The expert Council on healthcare of the Federation Council Committee on social policy [Otsenka sostoyaniya okazaniya meditsinskoi pomoshchi bol’nym c Limfomoi Khodzhkina i sistemnoi anaplasticheskoi krupnokletochnoi limfomoi. Ekspertnyi sovet po zdravookhraneniyu Komiteta Soveta Federatsii po sotsial’noi politike (in Russian)]. Moscow. 2015.

22. Instructions for use of medicinal product for medical use Adcetris® [Instruktsiya po primeneniyu lekarstvennogo preparata dlya meditsinskogo primeneniya Adtsetris® (in Russian)].

23. Resolution of the Government of the Russian Federation from 19.12.2015 g. №1382 “On the Programme of state guarantees of free rendering to citizens of medical aid for 2016” [Postanovlenie Pravitel’stva Rossiiskoi Federatsii ot 19.12.2015 g. №1382 «O Programme gosudarstvennykh garantii besplatnogo okazaniya grazhdanam meditsinskoi pomoshchi na 2016 god» (in Russian)].

24. The official website of the Russian Federation for posting information about placing orders http://zakupki.gov.ru/epz/main/public/home.html. Accessed: 10.12.2016.

25. Kolbin A.S., Vilyum I.A., Proskurin M.A., Balykina Yu.  E. Klinicheskaya farmakologiya i terapiya. 2016; 25 (2): 90-96.

26. Official site of Territorial Fund OMS of St.-Petersburg. http://www.spboms.ru/. Accessed: 10.12.2016.

27. On approval of the branch standard “clinico-economic studies. General provisions”: the order No. 163 of the Ministry of Health of the Russian Federation of 27.05.2011 http://clinvest.ru/news/item/otraslevoj-standart-kliniko-ekonomicheskie-issledovaniya-obshiepolozheniya. Accessed: 13.12.2016.


For citation:


Kolbin A.S., Vilum I.A., Proskurin М.A., Balykina Y.E. PHARMACOECONOMIC ANALYSIS OF BRENTUXIMAB VEDOTIN THERAPY IN RELAPSED OR REFRACTORY CD30+ SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA IN PATIENTS OVER 18 YEARS OF AGE: HEALTH BUDGET IMPACT ANALYSIS. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2017;10(1):39-45. (In Russ.) https://doi.org/10.17749/2070-4909.2017.10.1.039-045

Views: 209


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)